Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

CORCEPT THERAPEUTICS INC

Form 8-K May 09, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Date of Report: May 09, 2007 (Date of earliest event reported)

Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter)

CA

(State or other jurisdiction of incorporation) 000-50679 (Commission File Number) 77-0487658 (IRS Employer Identification Number) 149 Commonwealth Drive (Address of principal executive offices) 94025

(Address of principal executive offices) 94025

(Zip Code)

650-327-3270

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On May 9, 2007 Corcept Therapeutics issued a press release announcing its financial results for the quarter ended March 31, 2007. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:

None

(b) Pro forma financial information:

None

(c) Shell company transactions:

None

(d) Exhibits

Press Release dated May 9, 2007

99.1 Press Release of Corcept Therapeutics Incorporated dated May 09, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 09, 2007

CORCEPT THERAPEUTICS INCORPORATED

By: <u>/s/ Anne LeDoux</u>

Anne LeDoux

Vice President & Controller

Exhibit Index Exhibit No. Description 99.1 Press Release of Corcept Therapeutics Incorporated dated May 09, 2007